Lipitor Ad Suggests Lower Rhabdomyolysis Risk Than Other Statins, FDA Says
Executive Summary
A direct-to-consumer print ad for Pfizer's Lipitor suggests the product is not associated with the same risk of rhabdomyolysis as other statins, a letter from FDA's Division of Drug Marketing, Advertising & Communications maintains